Skip to content
Clinical ResearchResearch compoundModerate evidence

Tesofensine

Experimental anti-obesity drug that prolongs the action of three brain messengers and strongly reduces appetite; not approved.

StimulantDopaminergicStimulantDopaminergicDopamineNorepinephrineSerotoninnoo.affects.appetite
Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Pharmacology

ClassStimulant · Dopaminergic
Primary targetTriple monoamine reuptake inhibition (dopamine, norepinephrine, serotonin)
Targets3 receptor targets
Half-lifeAbout 8 days (~220 hours), which is why it is dosed once daily in the morning
OnsetHours to absorb, but the clinical effect builds over weeks with daily dosing
EvidenceModerate evidence
Affected systemsDopamineNorepinephrineSerotoninnoo.affects.appetite

Contents

DETAILED OVERVIEW

What is Tesofensine?

Tesofensine is an experimental drug candidate originally developed against Parkinson's and Alzheimer's disease. It caused striking weight loss in trials, so interest turned to treating obesity. It is not approved for obesity anywhere and is not a dietary supplement.

It blocks the reuptake of dopamine, norepinephrine and serotonin into nerve cells, so these substances keep acting longer, which reduces appetite and increases the feeling of fullness. In one human trial, those given the larger dose lost on average 9–11% of body weight over several months. The most common complaint is dry mouth; insomnia, a fast heartbeat and a rise in blood pressure also occur. It should be avoided in heart and blood vessel disease, anxiety, together with MAO inhibitors and in pregnancy. It is not named on the doping list, but as a strong stimulant it may fall among the stimulants on the list, so competing athletes should check.

Mechanism

Blocks reuptake of dopamine, norepinephrine and serotonin

Half-life

About 8 days (once-daily morning dose)

Legal status

In development, not approved

Receptor profile

  • Dopamine / norepinephrine / serotonin transporters (DAT/NET/SERT)Strong
  • Satiety and energy expenditure (hypothalamus)Strong
  • Hypothalamic GABAergic tone (indirect)Moderate

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • Dry mouth, the most common and dose-dependent complaint
  • Insomnia and disrupted sleep, especially with late dosing
  • Increased heart rate and modest blood pressure rise (about 7 bpm on average)
  • Constipation and gastrointestinal discomfort
  • Restlessness, tremor and agitation from monoaminergic overstimulation
  • Mood changes, irritability and anxiety at higher doses

Contraindications · 5

  • Cardiovascular disease, arrhythmia, uncontrolled hypertension: due to the heart-rate and blood-pressure raising effect
  • Concurrent MAO inhibitors or serotonergic drugs: risk of serotonin syndrome
  • Anxiety disorder, panic disorder or mood disorder: the stimulant effect may worsen them
  • Pregnancy and breastfeeding: safety not established, avoid
  • Not an approved medicine: not recommended without clinical supervision

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

Tesofensine is an investigational weight-loss drug that strongly suppresses appetite and boosts the feeling of fullness. In Phase 2 trials, participants lost a notable amount of body weight over 24 weeks, because the compound raises the levels of three brain signaling chemicals at once, affecting both energy and hunger. It is also being studied for rare, severe appetite disorders, but it remains a clinical-stage drug, not yet an approved product.

Telegram

Have a question about Tesofensine?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeStimulant
FormulaC17H23Cl2NO
UpdatedOctober 14, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.